secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apellis Pharmaceuticals, Inc. (APLS)
CIK:        0001492422
Form:       8-K
Filed at:   2023-01-05T23:59:59+00:00
Accession:  0001193125-23-001962
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Apellis CMO Federico Grossi departs; Caroline Baumal named new CMO effective Jan 3, 2023
--------------------------------------------------------------------------------

- Federico Grossi, M.D., Ph.D., leaves as Chief Medical Officer effective Jan 3, 2023 to pursue new career opportunities.
- Caroline Baumal, M.D., appointed CMO effective Jan 3, 2023, succeeding Dr. Grossi.
- Dr. Grossi will continue at Apellis through Feb 28, 2023 to assist transition and pegcetacoplan launch preparations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1492422/000119312523001962/0001193125-23-001962-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1492422/000119312523001962/d436534d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-001962

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer